| Source: |
| Type: |
| Tumor cell migration is a critical process in cancer progression and metastasis, which is the spread of cancer cells from the primary tumor to distant sites in the body. |
| Pancreatic Cancer: Hypoxia (low oxygen tension) is commonly found in solid tumors. Hypoxia-inducible factor-1 (HIF-1),is a key mediator of the cellular response to hypoxia and is overexpressed in a wide variety of solid tumors, including pancreatic cancer. Nanog is highly expressed in CSCs compared to normal cells [93–97] HIF-1↑ |
| 1362- | Ash, | GEM, | Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Hs766t |
| 6073- | CHL, | GEM, | Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis |
| - | in-vitro, | PC, | NA |
| 1584- | Citrate, | Anticancer effects of high-dose extracellular citrate treatment in pancreatic cancer cells under different glucose concentrations |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 |
| 11- | CUR, | Curcumin inhibits hypoxia-induced epithelial‑mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway |
| - | in-vitro, | PC, | PANC1 |
| 476- | CUR, | The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer |
| - | in-vitro, | PC, | PATU-8988 | - | in-vitro, | PC, | PANC1 |
| 19- | Deg, | Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 |
| 22- | EGCG, | Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics |
| - | in-vitro, | PC, | CD133+ | - | in-vitro, | PC, | CD44+ | - | in-vitro, | PC, | CD24+ | - | in-vitro, | PC, | ESA+ |
| - | in-vitro, | PC, | NA |
| 1186- | Gb, | Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis |
| - | in-vitro, | PC, | NA | - | in-vitro, | Nor, | HUVECs | - | in-vivo, | PC, | NA |
| 2882- | HNK, | Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling |
| - | in-vitro, | PC, | PANC1 |
| 1920- | JG, | TQ, | PLB, | Natural quinones induce ROS-mediated apoptosis and inhibit cell migration in PANC-1 human pancreatic cancer cell line |
| - | in-vitro, | PC, | PANC1 |
| 4520- | MAG, | Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling |
| - | vitro+vivo, | PC, | PANC1 |
| 524- | MF, | Inhibition of Angiogenesis Mediated by Extremely Low-Frequency Magnetic Fields (ELF-MFs) |
| - | vitro+vivo, | PC, | MS-1 | - | vitro+vivo, | PC, | HUVECs |
| 4976- | Nimb, | Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition |
| - | vitro+vivo, | PC, | NA |
| 1225- | OLST, | Orlistat Induces Ferroptosis in Pancreatic Neuroendocrine Tumors by Inactivating the MAPK Pathway |
| - | vitro+vivo, | PC, | NA |
| 57- | QC, | Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo |
| - | vitro+vivo, | PC, | PC3 |
| 3035- | RosA, | Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling |
| - | in-vitro, | PC, | NA | - | in-vivo, | NA, | NA |
| 3045- | SK, | Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2) |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 962- | TQ, | Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | Nor, | hTERT-HPNE | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | Bxpc-3 |
| 4853- | Uro, | Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer |
| - | vitro+vivo, | PC, | MIA PaCa-2 | - | in-vitro, | NA, | PANC1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:21 Cells:% prod#:% Target#:326 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid